UroGen Pharma(URGN) - 2025 Q3 - Quarterly Results

Exhibit 99.1 UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum PRINCETON, N.J. November 6, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2025, and provided an overview of recent developments. "Our launch of ZUSDURI, the first and only FDA-approved medicine for adults with rec ...